Hervé Hoppenot leaves Novartis to become Incyte CEO
This article was originally published in Scrip
Executive Summary
Former president of Novartis Oncology Hervé Hoppenot has left the pharma giant to take up the mantle as president and CEO of Incyte. Mr Hoppenot, who will also join the Incyte board of directors, succeeds Dr Paul A Friedman who is retiring but willremain on the board.